摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

3-[4-(methylsulfonyl)phenyl]-2-phenyl-2-cyclopenten-1-one

中文名称
——
中文别名
——
英文名称
3-[4-(methylsulfonyl)phenyl]-2-phenyl-2-cyclopenten-1-one
英文别名
3[4-(methylsulfonyl) phenyl]-2-phenyl-2-cyclopenten-1-one;3-(4-Methanesulfonyl-phenyl)-2-phenyl-cyclopent-2-enone;3-(4-methylsulfonylphenyl)-2-phenylcyclopent-2-en-1-one
3-[4-(methylsulfonyl)phenyl]-2-phenyl-2-cyclopenten-1-one化学式
CAS
——
化学式
C18H16O3S
mdl
——
分子量
312.389
InChiKey
UNHXJQNYRJHGEJ-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    2.6
  • 重原子数:
    22
  • 可旋转键数:
    3
  • 环数:
    3.0
  • sp3杂化的碳原子比例:
    0.17
  • 拓扑面积:
    59.6
  • 氢给体数:
    0
  • 氢受体数:
    3

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为产物:
    参考文献:
    名称:
    2,3-Diarylcyclopentenones as Orally Active, Highly Selective Cyclooxygenase-2 Inhibitors
    摘要:
    Cyclopentenones containing a 4-(methylsulfonyl)phenyl group in the 3-position and a phenyl ring in the 2-position are selective inhibitors of cyclooxygenase-2 (COX-2). The selectivity for COX-2 over COX-1 is dramatically improved by substituting the 2-phenyl group with halogens in the meta position or by replacing the phenyl ring with a 2- or 3-pyridyl ring. Thus the 3,5-difluorophenyl derivative 7 (L1776,967) and the 3-pyridyl derivative 13 (L-784,506) are particularly interesting as potential antiinflammatory agents with reduced side-effect profiles. Both exhibit good oral bioavailability and are potent in standard models of pain, fever, and inflammation yet have a much reduced effect on the GI integrity of rats compared to standard nonsteroidal antiflammatory drugs.
    DOI:
    10.1021/jm980642l
点击查看最新优质反应信息

文献信息

  • Combination therapy for the treatment of cancer
    申请人:Pharmacia Corporation
    公开号:US20030216410A1
    公开(公告)日:2003-11-20
    The present invention relates to methods for treatment or prevention of neoplasia disorders using protein tyrosine kinase inhibitors in combination with cyclooxygenase inhibitors, in particular cyclooxygenase-2 selective inhibitors.
    本发明涉及使用蛋白酪氨酸激酶抑制剂与环氧合酶抑制剂,特别是环氧合酶-2选择性抑制剂,联合治疗或预防肿瘤性疾病的方法。
  • Antiangiogenic combination therapy for the treatment of cancer
    申请人:——
    公开号:US20020103141A1
    公开(公告)日:2002-08-01
    The present invention provides combinations of a DNA topoisomerase I inhibiting agent and a selective COX-2 inhibiting agent for preventing, treating, and/or reducing the risk of developing a neoplasia disorder in a mammal.
    本发明提供了一种DNA拓扑异构酶I抑制剂和选择性COX-2抑制剂的组合物,用于预防、治疗和/或减少哺乳动物发生肿瘤性疾病的风险。
  • Method for the treatment and prevention of cachexia
    申请人:Washington University
    公开号:US20030087942A1
    公开(公告)日:2003-05-08
    Cachexia, including anorexia and other forms of weight loss, is a frequent complication of acute and chronic infections, and result from induction of cytokines, prostaglandins, and other inflammatory mediators that are critical for pathogen elimination. The present invention includes methods for the treatment or prevention of cachexic conditions while maintaining the production of factors essential for infection control through the administration of an effective amount of a cyclooxygenase-2 selective inhibiting compound.
    消瘦症,包括厌食和其他形式的体重减轻,是急性和慢性感染的常见并发症,由细胞因子、前列腺素和其他炎症介质的诱导引起,这些介质对病原体清除至关重要。本发明包括通过给予有效量的环氧合酶-2选择性抑制化合物来治疗或预防消瘦症状,同时保持对感染控制至关重要的因子的产生的方法。
  • Method of using a COX-2 inhibitor and a TACE inhibitors as a combination therapy
    申请人:Pharmacia Corporation
    公开号:US20040122011A1
    公开(公告)日:2004-06-24
    The present invention provides compositions and methods to treat, prevent or inhibit a neoplasia, a neoplasia-related disorder, pain, inflammation, an inflammatory-related disorder, a vaso-occlusive event or a vaso-occlusive-related disorder in a mammal using a combination of a COX-2 inhibitor and a TACE inhibitor.
    本发明提供了一种使用COX-2抑制剂和TACE抑制剂的组合物和方法,以治疗、预防或抑制哺乳动物中的肿瘤、肿瘤相关疾病、疼痛、炎症、炎症相关疾病、血管闭塞性事件或血管闭塞性相关疾病。
  • Method of using a COX-2 inhibitor and an alkylating-type antineoplastic agent as a combination therapy in the treatment of neoplasia
    申请人:Pharmacia Corporation
    公开号:US20040072889A1
    公开(公告)日:2004-04-15
    The present invention provides compositions and methods to treat, prevent or inhibit a neoplasia or a neoplasia-related disorder in a mammal using a combination of a COX-2 inhibitor and an alkylating-type antineoplastic agent.
    本发明提供了一种使用COX-2抑制剂和烷基化类抗肿瘤药物的组合来治疗、预防或抑制哺乳动物中的肿瘤或与肿瘤相关的疾病的组合物和方法。
查看更多

同类化合物

(E,Z)-他莫昔芬N-β-D-葡糖醛酸 (E/Z)-他莫昔芬-d5 (4S,5R)-4,5-二苯基-1,2,3-恶噻唑烷-2,2-二氧化物-3-羧酸叔丁酯 (4R,4''R,5S,5''S)-2,2''-(1-甲基亚乙基)双[4,5-二氢-4,5-二苯基恶唑] (1R,2R)-2-(二苯基膦基)-1,2-二苯基乙胺 鼓槌石斛素 高黄绿酸 顺式白藜芦醇三甲醚 顺式白藜芦醇 顺式己烯雌酚 顺式-桑皮苷A 顺式-曲札芪苷 顺式-二苯乙烯 顺式-beta-羟基他莫昔芬 顺式-a-羟基他莫昔芬 顺式-3,4',5-三甲氧基-3'-羟基二苯乙烯 顺式-1,2-二苯基环丁烷 顺-均二苯乙烯硼酸二乙醇胺酯 顺-4-硝基二苯乙烯 顺-1-异丙基-2,3-二苯基氮丙啶 阿非昔芬 阿里可拉唑 阿那曲唑二聚体 阿托伐他汀环氧四氢呋喃 阿托伐他汀环氧乙烷杂质 阿托伐他汀环(氟苯基)钠盐杂质 阿托伐他汀环(氟苯基)烯丙基酯 阿托伐他汀杂质D 阿托伐他汀杂质94 阿托伐他汀内酰胺钠盐杂质 阿托伐他汀中间体M4 阿奈库碘铵 银松素 铒(III) 离子载体 I 钾钠2,2'-[(E)-1,2-乙烯二基]二[5-({4-苯胺基-6-[(2-羟基乙基)氨基]-1,3,5-三嗪-2-基}氨基)苯磺酸酯](1:1:1) 钠{4-[氧代(苯基)乙酰基]苯基}甲烷磺酸酯 钠;[2-甲氧基-5-[2-(3,4,5-三甲氧基苯基)乙基]苯基]硫酸盐 钠4-氨基二苯乙烯-2-磺酸酯 钠3-(4-甲氧基苯基)-2-苯基丙烯酸酯 重氮基乙酸胆酯酯 醋酸(R)-(+)-2-羟基-1,2,2-三苯乙酯 酸性绿16 邻氯苯基苄基酮 那碎因盐酸盐 那碎因[鹼] 达格列净杂质54 辛那马维林 赤藓型-1,2-联苯-2-(丙胺)乙醇 赤松素 败脂酸,丁基丙-2-烯酸酯,甲基2-甲基丙-2-烯酸酯,2-甲基丙-2-烯酸